BCM
MGNX icon

Bayesian Capital Management’s MacroGenics MGNX Stock Holding History

Bayesian Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,132
Closed -$91.7K – 867
2023
Q2 		$91.7K Sell
17,132
-4,500
-21% -$27.8K 0.01% 698
2023
Q1 		$155K Buy
+21,632
New +$130K 0.02% 642
2019
Q2 		– Sell
-10,384
Closed -$187K – 616
2019
Q1 		$187K Buy
+10,384
New +$179K 0.04% 480

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's MGNX Position: Q3 2023 in Review

Bayesian Capital Management sold out of MacroGenics (MGNX) in Q3 2023, closing a stake of 17,132 shares — an estimated $91.7K sold.

Bayesian Capital Management first reported a position in MGNX in Q1 2019 and held it in 3 quarters. The position peaked at $187K in Q1 2019. 127 funds tracked by Wall St. Rank hold MGNX as of Q3 2023.

  • Bayesian Capital Management reported no remaining MacroGenics position as of Q3 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 17,132 MacroGenics shares in Q3 2023, an estimated $91.7K.
  • Bayesian Capital Management first reported a position in MacroGenics in Q1 2019 and held it in 3 quarters.
  • Bayesian Capital Management's MacroGenics position peaked at $187K in Q1 2019.
  • 127 funds tracked by Wall St. Rank held MacroGenics as of Q3 2023.

Based on Bayesian Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.